Cabometyx is an English word starting with the letter C. With 2 example sentences you'll see exactly how it works in context.
Cabometyx in a sentence
Context around Cabometyx
- Average sentence length in these examples: 27 words
- Position in the sentence: 2 start, 0 middle, 0 end
- Sentence types: 2 statements, 0 questions, 0 exclamations
Corpus analysis for Cabometyx
- In this selection, "cabometyx" usually appears near the start of the sentence. The average example has 27 words, and this corpus slice is mostly made up of statements.
- Around the word, makes and alone stand out and add context to how "cabometyx" is used.
- Recognizable usage signals include also makes cabometyx a kidney and combination of cabometyx with against. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "cabometyx" sits close to words such as aabc, aacr and aacsb, which helps place it inside the broader word index.
Example types with cabometyx
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
Exelixis also makes Cabometyx, a kidney cancer drug he expects to be worth $1 billion in 2020. (17 words)
This trial evaluated the combination of Cabometyx with against Cabometyx alone in individuals with advanced or metastatic clear cell or non-clear cell renal cell carcinoma (RCC) who had previously shown progression on immune checkpoint inhibitor therapy. (37 words)
This trial evaluated the combination of Cabometyx with against Cabometyx alone in individuals with advanced or metastatic clear cell or non-clear cell renal cell carcinoma (RCC) who had previously shown progression on immune checkpoint inhibitor therapy. (37 words)
Exelixis also makes Cabometyx, a kidney cancer drug he expects to be worth $1 billion in 2020. (17 words)
Example sentences (2)
This trial evaluated the combination of Cabometyx with against Cabometyx alone in individuals with advanced or metastatic clear cell or non-clear cell renal cell carcinoma (RCC) who had previously shown progression on immune checkpoint inhibitor therapy.
Exelixis also makes Cabometyx, a kidney cancer drug he expects to be worth $1 billion in 2020.